Comparative Pharmacology
Head-to-head clinical analysis: COTRIM versus XEPI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COTRIM versus XEPI.
COTRIM vs XEPI
Head-to-head clinical comparison of therapeutic indices and safety profiles.
COTRIM is a combination of trimethoprim and sulfamethoxazole; sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, sequentially blocking bacterial folate synthesis.
Ozenoxacin is a topical fluoroquinolone antibiotic that inhibits bacterial DNA replication by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, leading to cell death.
Urinary tract infectionsOtitis mediaBronchitisTraveler's diarrheaShigellosisPneumocystis jirovecii pneumonia (prophylaxis and treatment)Toxoplasmosis (prophylaxis in immunocompromised)Acute exacerbations of chronic obstructive pulmonary diseaseMethicillin-resistant Staphylococcus aureus (MRSA) skin infections
Impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adults and pediatric patients aged 2 months and older.
1 double-strength tablet (160 mg trimethoprim + 800 mg sulfamethoxazole) orally every 12 hours for 5-14 days; 15-20 mg/kg/day (based on trimethoprim) IV divided every 6-8 hours for severe infections.
Topical: Apply a pea-sized amount to the affected area twice daily. For moderate to severe plaque psoriasis, initiate treatment with clobetasol propionate spray 0.05% applied twice weekly (Sunday and Thursday) to the scalp and/or body lesions. For plaque psoriasis under occlusion or on limited areas, clobetasol propionate foam 0.05% applied twice daily. For scalp psoriasis, clobetasol propionate shampoo 0.05% applied once daily to the dry scalp, left for 15 minutes, then rinsed. For steroid-responsive dermatoses, clobetasol propionate ointment, cream, or lotion 0.05% applied sparingly to the affected area twice daily (morning and night) for up to 2 weeks; re-evaluate if no improvement. Maximum dose: 50 g/week of 0.05% preparation; for scalp applications, 50 mL/week.
None Documented
None Documented
Sulfamethoxazole: 9-11 hours (normal renal function); trimethoprim: 8-10 hours. Extended in renal impairment (SMX up to 30h, TMP up to 24h).
Terminal elimination half-life is approximately 8 hours in patients with normal renal function (creatinine clearance ≥90 mL/min). In moderate renal impairment (CrCl 30-59 mL/min), half-life extends to about 15 hours.
Trimethoprim is primarily metabolized by the liver via CYP450 enzymes (CYP3A4, CYP1A2) and excreted in urine; sulfamethoxazole undergoes N-acetylation and glucuronidation, also excreted renally.
Systemic absorption is minimal; metabolism in systemic circulation is negligible. If absorbed, it is not extensively metabolized.
Renal: 50-70% unchanged sulfamethoxazole, 15-30% N4-acetylated metabolite; trimethoprim: 50-60% unchanged, 10-20% metabolites. Biliary/fecal: minimal.
Approximately 80% eliminated renally as unchanged drug via glomerular filtration and tubular secretion. Approximately 20% eliminated in feces via biliary excretion.
Sulfamethoxazole: 70% bound to albumin; trimethoprim: 44% bound to alpha-1 acid glycoprotein and albumin.
Approximately 30% bound to plasma proteins, primarily albumin.
Sulfamethoxazole: 0.2-0.3 L/kg; trimethoprim: 1.3-2.0 L/kg. TMP distributes extensively into tissues, including CNS (50% of serum concentration).
Volume of distribution is approximately 0.2-0.3 L/kg, indicating primarily extracellular fluid distribution with limited tissue penetration.
Oral: 85-100% for both components; IV: 100%.
Intravenous: 100% bioavailable. Oral bioavailability not applicable as drug is only administered intravenously.
CrCl >30 mL/min: no adjustment; CrCl 15-30 mL/min: reduce dose by 50%; CrCl <15 mL/min: contraindicated unless for prophylaxis against Pneumocystis jirovecii, in which case use 50% dose.
No dosage adjustment is required in patients with renal impairment as topical absorption is minimal. Systemic toxicity is unlikely, but caution is advised in severe renal impairment due to potential accumulation of excipients. For oral formulations (not applicable), no data available.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, monitor liver function; Child-Pugh C: contraindicated due to risk of hepatotoxicity.
No dosage adjustment is required in patients with hepatic impairment based on low systemic absorption. However, in severe hepatic impairment (Child-Pugh C), systemic corticosteroid effects may be potentiated; use with caution and limit application area. For oral formulations (not applicable), no data available.
Pneumocystis jirovecii pneumonia: 15-20 mg/kg/day (based on trimethoprim) IV divided every 6-8 hours for 21 days; mild infections: 8-12 mg/kg/day oral divided every 12 hours; maximum: 640 mg/day trimethoprim.
Safety and efficacy in pediatric patients have not been established. Use is not recommended for children under 12 years of age due to higher risk of hypothalamic-pituitary-adrenal axis suppression. For children 12-17 years, apply the same dose as adults but limit treatment to 2 weeks; do not use under occlusion; avoid face, axillae, and groin. Maximum duration: 2 consecutive weeks.
Assess renal function; CrCl >30 mL/min: standard adult dosing; reduce dose or extend interval if CrCl 15-30 mL/min; avoid if CrCl <15 mL/min; monitor for electrolyte abnormalities and hypersensitivity.
No specific dose adjustment is needed, but elderly patients may have increased susceptibility to topical corticosteroid adverse effects due to age-related skin thinning. Use the lowest effective dose for the shortest duration. Monitor for skin atrophy, telangiectasias, and systemic absorption. Avoid use on large areas or under occlusion. Apply sparingly and discontinue if irritation occurs.
Fatal hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS); agranulocytosis, aplastic anemia, and other blood dyscrasias; use in patients with G6PD deficiency may cause hemolytic anemia.
None.
Monitor for hypersensitivity reactions; avoid use in elderly with renal impairment due to risk of sulfonamide-induced blood dyscrasias; monitor renal function and electrolytes (hyperkalemia with high doses); caution in folate deficiency; use with other drugs prolonging QT interval; monitor for neutropenia with prolonged therapy.
["Hypersensitivity reactions including anaphylaxis have been reported. Discontinue if rash or other allergic symptoms occur. Avoid prolonged use as it may result in overgrowth of non-susceptible organisms including fungi. For external use only; not for ophthalmic, oral, or intravaginal use."]
Hypersensitivity to sulfonamides or trimethoprim; severe hepatic injury; marked renal impairment (CrCl <15 mL/min) unless dialysis; megaloblastic anemia due to folate deficiency; pregnancy (especially first trimester) and lactation; infants <2 months of age; concurrent use with dofetilide (risk of QT prolongation).
["Hypersensitivity to ozenoxacin or any component of the formulation, or to other fluoroquinolones."]
Data Pending Review
Data Pending Review
Avoid high-potassium foods (e.g., bananas, oranges, potatoes) if on high doses or with renal impairment; avoid alcohol as it may cause disulfiram-like reaction; avoid folic acid-rich foods (e.g., liver) as they may reduce efficacy.
No clinically significant food interactions. XEPI is applied topically and not absorbed systemically; dietary restrictions are not required.
Pregnancy category C/D. First trimester: Folate antagonist; neural tube defects, cardiovascular malformations, cleft palate reported. Second/third trimester: Kernicterus risk in neonate due to bilirubin displacement; hemolytic anemia in G6PD deficiency. Avoid near term.
XEPI (cefepime, enmetazobactam) is classified as Pregnancy Category B based on animal studies. There are no adequate and well-controlled studies in pregnant women. For trimester 1, 2, and 3, the potential risk to the fetus is considered low based on animal data, but the drug should only be used if clearly needed. No specific teratogenic patterns have been identified.
Small amounts excreted in breast milk; M/P ratio unknown. May cause kernicterus in jaundiced infants or hemolysis in G6PD deficiency. Consider risks vs benefits; alternative agents preferred.
Cefepime is excreted into human milk in small amounts (M/P ratio approximately 0.03-0.05); enmetazobactam is likely excreted similarly but data are lacking. The low milk concentrations suggest minimal risk to a nursing infant, but caution is advised due to potential alteration of infant gut flora. The American Academy of Pediatrics considers cefepime compatible with breastfeeding.
Increased renal clearance in pregnancy may require higher doses; however, limited data. Standard dosing often maintained but adjust if renal impairment. Supplement with folate (5 mg daily) to mitigate teratogenicity.
Pregnancy-induced physiological changes (e.g., increased plasma volume, enhanced renal clearance) may lower drug concentrations. No specific dose adjustments for XEPI in pregnancy are established; however, standard adult dosing (2 g cefepime/0.5 g enmetazobactam every 8 hours) is recommended, with close monitoring of clinical response. Consider therapeutic drug monitoring if available, especially for severe infections.
Category C
Category C
Monitor for hyperkalemia, especially in elderly or patients with renal impairment; sulfonamide component can cause crystalluria — ensure adequate hydration; beware of hypoglycemia when used with sulfonylureas; avoid near term of pregnancy due to risk of kernicterus.
XEPI (ozenoxacin) is a topical antibiotic for impetigo. Apply a thin layer to affected area twice daily for 5 days. No systemic absorption; safe for children 2 months and older. Avoid use on large areas of damaged skin or in patients with known hypersensitivity to quinolones. Monitor for local irritation or allergic contact dermatitis.
Take with a full glass of water to prevent kidney stones.Complete the full course even if feeling better.Avoid prolonged sun exposure and use sunscreen due to photosensitivity risk.Report any rash, fever, sore throat, or unusual bruising immediately.Do not take if you are allergic to sulfa drugs.
Apply a thin layer of the cream to the infected skin area exactly as prescribed.Wash hands before and after applying the medication.Do not cover the treated area with bandages or dressings unless instructed by your doctor.Use for the full prescribed duration, even if symptoms improve, to prevent recurrence.Avoid sharing towels, clothing, or bedding to prevent spread of infection.Notify your doctor if skin irritation, rash, or signs of allergy develop.